FDA expands pediatric use of Bristol's HIV drug Sustiva

05/6/2013 | Drug Store News · RTT News

The FDA approved Bristol-Myers Squibb's Sustiva, or efavirenz, to treat HIV-1 patients ages 3 months to 3 years who weigh at least 7.7 pounds. The approval covers sprinkle administration when swallowing a capsule or tablet isn't possible. The drug was evaluated in three open-label trials involving 182 patients.

View Full Article in:

Drug Store News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY